Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm Kyowa Kirin Biologics Looking for Marketing Partners in Europe and US: Executive VP Kawaguchi
May 7, 2013
- Mochida Files NDA for PAH Treatment Treprostinil
May 7, 2013
- Daiichi Sankyo, Perosphere to Develop Anticoagulant Reversal Agent for Edoxaban
May 2, 2013
- Anticancer Agent Xtandi Receives Positive Opinion for Marketing Approval by EMA: Astellas
May 2, 2013
- Boehringer to Enter Oncology Market, Hire 100 MRs in Japan
May 2, 2013
- Boehringer Chief Says Japan Business Successful
May 2, 2013
- Astellas Vice President Miyokawa to Be Promoted to Representative Director
May 2, 2013
- Novartis Investigating Employee Involvement in Retracted Diovan Papers
May 1, 2013
- Torii Aims for Sales of 63 Billion Yen in FY2015, Expanding Allergen Field
May 1, 2013
- Torii to Launch Anti-HIV Drug Stribild Combination Tablets on May 14
May 1, 2013
- Eisai to Establish New Parenteral Plant to Manufacture Methycobal in China
May 1, 2013
- With Mucosta Pursuing Diquas, New Drugs Have Growing Presence in Market for Dry Eye Treatments
April 30, 2013
- UMN to Open Japan’s Biggest Biopharmaceutical Contract Manufacturing Facility; Success or Failure Could Determine the Future of this Business in Japan
April 30, 2013
- Ethical Drug Production to Exceed 12 Trillion Yen in 2020: Yano Research Institute
April 30, 2013
- Sandoz K.K. Applies for Gran Biosimilar
April 26, 2013
- Daiichi Sankyo Begins Nimotuzumab PIII Trials for Lung and Gastric Cancers
April 26, 2013
- Boehringer Filed NDA for Afatinib in Japan: Chairman
April 26, 2013
- Takeda Files NDA for Fixed-Dose Combination of Azilva/Amlodipine in Japan
April 26, 2013
- Edoxaban Will Be Key to Achieving Targets in Daiichi Sankyo’s New 5-Year Business Plan
April 26, 2013
- Takeda Initiates Voluntary Partial Recall for Azilva due to Incorrect Expiry Date on Packaging Carton
April 25, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…